MAP kinase ERK5 modulates cancer cell sensitivity to extrinsic apoptosis induced by death-receptor agonists

Mostra el registre complet Registre parcial de l'ítem

• dc.contributor.author Espinosa-Gil, Sergio
• dc.contributor.author Ivanova, Saska
• dc.contributor.author Alari-Pahissa, Elisenda
• dc.contributor.author Denizli, Melek
• dc.contributor.author Villafranca-Magdalena, Beatriz
• dc.contributor.author Viñas-Casas, Maria
• dc.contributor.author Bolinaga-Ayala, Idoia
• dc.contributor.author Gámez-García, Andrés
• dc.contributor.author Faundez-Vidiella, Claudia
• dc.contributor.author Colas, Eva
• dc.contributor.author López-Botet, M. (Miguel)
• dc.contributor.author Zorzano, Antonio
• dc.contributor.author Lizcano, José Miguel
• dc.date.accessioned 2023-12-12T06:58:07Z
• dc.date.available 2023-12-12T06:58:07Z
• dc.date.issued 2023
• dc.description.abstract Death receptor ligand TRAIL is a promising cancer therapy due to its ability to selectively trigger extrinsic apoptosis in cancer cells. However, TRAIL-based therapies in humans have shown limitations, mainly due inherent or acquired resistance of tumor cells. To address this issue, current efforts are focussed on dissecting the intracellular signaling pathways involved in resistance to TRAIL, to identify strategies that sensitize cancer cells to TRAIL-induced cytotoxicity. In this work, we describe the oncogenic MEK5-ERK5 pathway as a critical regulator of cancer cell resistance to the apoptosis induced by death receptor ligands. Using 2D and 3D cell cultures and transcriptomic analyses, we show that ERK5 controls the proteostasis of TP53INP2, a protein necessary for full activation of caspase-8 in response to TNFα, FasL or TRAIL. Mechanistically, ERK5 phosphorylates and induces ubiquitylation and proteasomal degradation of TP53INP2, resulting in cancer cell resistance to TRAIL. Concordantly, ERK5 inhibition or genetic deletion, by stabilizing TP53INP2, sensitizes cancer cells to the apoptosis induced by recombinant TRAIL and TRAIL/FasL expressed by Natural Killer cells. The MEK5-ERK5 pathway regulates cancer cell proliferation and survival, and ERK5 inhibitors have shown anticancer activity in preclinical models of solid tumors. Using endometrial cancer patient-derived xenograft organoids, we propose ERK5 inhibition as an effective strategy to sensitize cancer cells to TRAIL-based therapies.
• dc.description.sponsorship SE-G and AG-G: are recipients of a fellowship from FI-AGAUR (2020-FISDU-00575 and FI_B 00293, respectively). I.B.A. is recipient of a PIF fellowship from UAB. MV-C is recipient of a PFU fellowship (Ref. FPU21/01999). B.V.M. is recipient of a PFIS fellowship (ref. FI21/00271). JML acknowledges support from Spanish Ministry of Economy and Competitiveness (MINECO, SAF2015-64237-R), Spanish Ministry of Science and Innovation (PID2019-107561RB-I00 and PID2022-136391OB-I00), and co-funded by the European Regional Development Fund (ERDF, “A way to make Europe/Investing in your future”). E.C. was founded by Fundación Científica Asociación Española Contra el Cáncer (AECC, GCTRA1804MATI) and Generalitat de Catalunya (2021-SGR-01157). AZ acknowledges support by research grants from MINECO (PID2019-106209RB-I00), CIBERDEM (Instituto de Salud Carlos III), and from an ICREA “Academia” Award (Generalitat de Catalunya). ML-B acknowledges support by research grant PID2019-110609RB-C21 from MCIN/AEI/ 10.13039/501100011033.
• dc.format.mimetype application/pdf
• dc.identifier.citation Espinosa-Gil S, Ivanova S, Alari-Pahissa E, Denizli M, Villafranca-Magdalena B, Viñas-Casas M, Bolinaga-Ayala I, Gámez-García A, Faundez-Vidiella C, Colas E, Lopez-Botet M, Zorzano A, Lizcano JM. MAP kinase ERK5 modulates cancer cell sensitivity to extrinsic apoptosis induced by death-receptor agonists. Cell Death Dis. 2023 Nov 2;14(11):715. DOI: 10.1038/s41419-023-06229-6
• dc.identifier.doi http://dx.doi.org/10.1038/s41419-023-06229-6
• dc.identifier.issn 2041-4889
• dc.identifier.uri http://hdl.handle.net/10230/58518
• dc.language.iso eng
• dc.publisher Nature Research
• dc.relation.ispartof Cell Death Dis. 2023 Nov 2;14(11):715
• dc.relation.projectID info:eu-repo/grantAgreement/ES/1PE/SAF2015-64237-R
• dc.relation.projectID info:eu-repo/grantAgreement/ES/2PE/PID2019-107561RB-I00
• dc.relation.projectID info:eu-repo/grantAgreement/ES/3PE/PID2022-136391OB-I00
• dc.relation.projectID info:eu-repo/grantAgreement/ES/2PE/PID2019-106209RB-I00
• dc.relation.projectID info:eu-repo/grantAgreement/ES/2PE/PID2019-110609RB-C21
• dc.rights © The Author(s) 2023. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
• dc.rights.accessRights info:eu-repo/semantics/openAccess
• dc.rights.uri http://creativecommons.org/licenses/by/4.0/
• dc.subject.keyword Apoptosis
• dc.subject.keyword Cell signalling
• dc.title MAP kinase ERK5 modulates cancer cell sensitivity to extrinsic apoptosis induced by death-receptor agonists
• dc.type info:eu-repo/semantics/article
• dc.type.version info:eu-repo/semantics/publishedVersion